ArticleBMJ open2025
Interventions to lower cardiovascular disease risk factors among Asian Indian immigrants: a scoping review protocol.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionTo identify effective interventions to lower cardiovascular disease (CVD) risk factors among Asian Indian (AI) immigrants.As the second largest immigrant group in the USA, AI immigrants experience CVD prevalence rates as high as 13% among males and 4.4% among females; these rates are significantly higher than other Asian subgroups and the general US population. Despite extensive knowledge of CVD risk factors, there have been few cardioprotective interventions in this population. METHODS AND ANALYSIS: Interventional studies of first-generation AI immigrants aged 18-70 years, conducted between 2000 and 2025, will be identified, including randomised controlled trials, factorial and cross-over designs, and cluster randomised trials. We will include AIs with and without a specific family history of CVD, or personal history of type 2 diabetes mellitus, hyperlipidaemia or obesity. Exclusion criteria include AIs born in the USA or visiting.The Arksey and O'Malley methodology framework and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews will be used for analysis. A preliminary review of interventions to lower the CVD risk in AIs will guide the research questions (stage 1). Relevant articles published between 2000 and 2025 will be retrieved using electronic databases and search terms (stage 2). Two independent reviewers will select studies based on eligibility criteria (stage 3). Reviewers will determine eligibility status, screen full texts and retrieve relevant publications. Reviewers will extract data, capturing study design, sample characteristics, types of interventions, outcomes and key findings (stage 4). A summary of results will be presented (stage 5). The review will identify the most effective interventions, potential areas for future research and practical recommendations to improve CVD outcomes among AI immigrants. ETHICS AND DISSEMINATION: Included studies will meet ethical standards in research. Findings will be disseminated through manuscripts, presentations at relevant conferences and community outreach programmes to promote effective interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.